Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

Core Drivers in the Evolution to Pharma 3.0

In the Ernst & Young Pharma 3.0 ecosystem, companies will need to shift from simply producing new medicines to demonstrating improvements in health outcomes via initiatives such as smartphone apps, educational websites, social media platforms, wireless devices and other programmes.

Patrick Flochel at Ernst & Young LLP (June 2011)

    View full article    |    Back to Industry Insight section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |